NewcelX shares rise 11.36% premarket after updated corporate presentation highlights Type 1 Diabetes focus and leadership expansion.

NewcelX surged 11.36% in premarket trading following the release of an updated corporate presentation on Jan. 29, 2026, which highlighted its sharpened strategic focus on Type 1 Diabetes cell therapy, recent scientific advancements, and new additions to its Scientific Advisory Board and leadership team. The presentation, unveiled ahead of spring 2026 investor and partnering conferences including BIO-Europe Spring, emphasized the company’s progress in restoring endogenous insulin production through regenerative medicine and reinforced its clinical development priorities. Management also announced plans to engage with stakeholders at upcoming conferences, underscoring confidence in near- and mid-term value-creation milestones. The CEO highlighted the strategic importance of the appointments, which enhance the company’s expertise in cell therapy development and commercialization, as key factors driving investor optimism.